Lanean...
DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
Heart failure (HF) continues to be a major global health problem with a notable impact in terms of morbidity and mortality and so, in consequence, with a large unmet necessity for new therapies. The inhibition of sodium–glucose cotransporter 2 (SGLT2) causes glycosuria and natriuresis, leading to re...
Gorde:
| Argitaratua izan da: | Drugs Context |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioExcel Publishing Ltd
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7051244/ https://ncbi.nlm.nih.gov/pubmed/32165892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2019-11-3 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|